HLA-C Antikörper (PE)

Produktnummer ABIN7505981

Dieser Anti-HLA-C-Antikörper ist ein Maus-Monoklonal-Antikörper zum Nachweis von HLA-C in FACS. Geeignet für Human und Non-Human Primate.

Kurzübersicht für HLA-C Antikörper (PE) (ABIN7505981)

Target: HLA-C (Major Histocompatibility Complex Class I C (HLA-C))

Reaktivität: Human, Non-Human Primate

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser HLA-C Antikörper ist konjugiert mit PE

Applikation: Flow Cytometry (FACS)

Klon: DT-9

Produktdetails anti-HLA-C Antikörper (PE)

Verwendungszweck: Anti-HLA-C PE

Spezifität: The mouse monoclonal antibody DT-9 recognizes an extracellular epitope on HLA-C member of MHC class I molecules. It does not crossreact with HLA-A or HLA-B allotypes.

Aufreinigung: Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Immunogen: Purified MHC class I molecules of tamarin origin

Isotyp: IgG2b

Anwendungsinformationen

Applikationshinweise: Flow cytometry: The reagent is designed for analysis of human blood cells using 10 μL reagent / 100 μL of whole blood or 10⁶ cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

Details zu HLA-C

Target: HLA-C (Major Histocompatibility Complex Class I C (HLA-C))

Andere Bezeichnung: HLA-C

Hintergrund: Major histocompatibility complex, class I, C,HLA-C, a member of MHC class I glycoproteins, is one of polymorphysm typing targets, which are important for transplantation. The HLA system plays an important role in the occurrence and outcome of infectious diseases. The structural spike and the nucleocapsid proteins of the novel coronavirus SARS-CoV-2, which causes coronavirus disease 2019 (COVID-19), are reported to contain multiple Class I epitopes with predicted HLA restrictions. Individual HLA genetic variation may help explain different immune responses to a virus across a population. It has been described that HLA-C interacts with human herpesvirus 8 MIR1 protein.,HLC-C, D6S204, PSORS1, HLA-JY3

Gen-ID: 3107

UniProt: P10321

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Human Leukocyte Antigen (HLA) in Adaptive Immune Response